Dialysis News and Research

Latest Dialysis News and Research

State news: Ariz. may cut fewer from Medicaid; Pa. adultbasic closes

In a meeting with the Obama administration Monday, Gov. Jan Brewer proposed some Medicaid changes that she hopes will allow Arizona to drop fewer people than previously proposed from the state's Medicaid rolls. Brewer's office already has received permission to cut coverage for 250,000 members, mostly childless adults, as the state tries to close an ongoing budget shortfall.

2 Mar 2011

Tengion prices $31.4 million through private placement financing

Tengion, Inc., a leader in regenerative medicine, today announced that it has entered into definitive agreements with certain investors in connection with a PIPE financing transaction pursuant to registration exemptions under the Securities Act of 1933, as amended.

1 Mar 2011

Hotspur Technologies announces first clinical use of its Keeper Embolectomy Catheter

Hotspur Technologies announced today that Dr. Thomas DiBartholomeo of Fairfield, CT, performed the first clinical use of its Keeper Embolectomy Catheter. The Keeper Catheter enables physicians to clear clot formation within arteries, while also incorporating the capability of injecting physician-specified fluids directly through the balloon catheter.

28 Feb 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

High radiation doses can increase risk of cancer in dialysis patients

High radiation doses put a significant number of dialysis patients at increased risk of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

25 Feb 2011

Study: More effective therapies needed for diabetes patients with ESRD

Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.

24 Feb 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011

Artificial blood vessel could be available ‘off the shelf’ soon

Soon artificial blood vessels could be available ‘off the shelf’. This would mean that heart bypass patients would not have to be subjected to a minor operation to graft veins from other parts of their body. This would also make life easier for surgeons as well.

20 Feb 2011

Redsense safety device receives 8 hour FDA clinical clearance for nocturnal dialysis

The Redsense safety device is the only device cleared by FDA to monitor patients for potential blood loss from the hemodialysis needle puncture site. With an 8 hour FDA clinical clearance, Redsense is available to help protect patients undergoing treatment in clinics for longer than 5 hours - such as Nocturnal Dialysis.

19 Feb 2011

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD).

17 Feb 2011

Roundup: States grapple with high health costs, Medicaid squeeze

Gov. Scott Walker's budget repair bill would give his administration sweeping powers to reshape state health programs covering more than 1 million state residents. Under the bill, the administration's rewrite of the Medicaid program would be reviewed only by the Legislature's budget committee, which has a broader margin of control for majority Republican lawmakers than any other legislative committee.

16 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Cantel Medical acquires ConFirm's sterilization monitoring business

CANTEL MEDICAL CORP., through its Crosstex International subsidiary, has further expanded its infection prevention and control business by purchasing the sterilization monitoring business of ConFirm Monitoring Systems, Inc. Based in Denver, Colorado, ConFirm is one of the leading providers of biological monitoring services in North America.

14 Feb 2011

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

AngioDynamics announced today the launch of a new Morpheus® SMART PICC bedside insertion kit and new 5 French Dual Lumen Peripherally Inserted Central Catheter (PICC) as part of the continued growth of its Morpheus SMART PICC line.

14 Feb 2011

AHRQ: $25.3 billion spent for kidney disease treatment every year

Overall, an average of 3.7 million adults in the United States were treated for kidney disease each year between 2003 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. Kidney disease can lead to renal failure and may be caused by diabetes, high blood pressure and heart disease.

11 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011